"Highly Active Anti-Retroviral Therapy Does Not Protect Macaques from Experimental SHIV Challenge."

According to an abstract submitted by the authors to the Fourth European Conference on Experimental AIDS Research, held June 18-21, 1999 in Tampere, Finland, "Objectives: To evaluate, in the model of macaques inoculated with highly pathogenic SHIV 89.6P, the efficacy of HAART against accidental intravenous exposure to HIV. Materials and Methods: Three groups of four cynomolgus macaques were inoculated intravenously with 50 MID₅₀ of a monkey PBMC-grown SHIV 89.6P cell-free stock. Animals were treated with placebo, or the association of AZT (4.5 mg/kg), 3TC (2.5 mg/kg), and Indinavir (20 mg/kg), administered twice a day at 6 to 8 hour intervals and by the oral...

Want to see the full article?

• Purchase this article for only $3.00